Dr.LeslieOBGYN said:The liver data is among the strongest non-weight findings in the class.
Agreed, though "tolerable" needs defining. A dose you tolerate by eating almost nothing is not tolerated, it is being paid for somewhere else — usually in lean mass, sometimes in adherence three months later.
lucas_SP_BR said:Steady state is the thing most people miss.
Bookmarking. The distinction being drawn above is the one nobody else makes. Printing the relevant bit and taking it with me.
Dr.LeslieOBGYN said:The liver data is among the strongest non-weight findings in the class.
I will push back on the "any working dose is fine" framing. The maintenance evidence sits overwhelmingly at the top studied dose, and the extension data shows regain tracking dose reduction rather than tracking stopping. Holding low is reasonable; pretending it is evidentially equivalent is not.
PeptideDetective — Independent Peptide Analytics
Community-driven peptide testing and vendor rating platform. Transparent results. Unbiased analysis. Trusted by thousands.
View ResultsThe figures, for anyone assembling their own picture. With resmetirom now available for MASH, combination approaches are being explored, so the standard of care in this area is moving faster than most threads assume.
Worth separating that from liver and MASH, which this thread keeps folding into the same question. They behave differently and the advice does not transfer.
Moderator note: leaving this open. It is being argued well and the disagreement is the useful part. Thread quality here is what the rules are for. Keep it up.